Skip to main content
. 2014 Oct 28;7(2):157–164. doi: 10.1007/s12402-014-0154-x

Table 4.

Incidence of adverse events (AEs) and serious adverse events (SAEs) in 28 patients that physicians deemed at least possibly related to MPH (adverse drug reactions, ADR), by System Organ Class and Preferred Term

MedDRA system organ class AE SAE Total
Preferred term N % N % N %
Total of patients 262 100 262 100 262 100
Patients with ADR 27 10.3 1 0.4 28 10.7
Metabolism and nutritional disorders 11 4.2 1 0.4 12 4.6
 Anorexia 11 4.2 1 0.4 12 4.6
Nervous system disorders 10 3.8 0 0.0 10 3.8
 Dizziness 1 0.4 0 0.0 1 0.4
 Agitation 2 0.8 0 0.0 2 0.8
 Confusional state 1 0.4 0 0.0 1 0.4
 Headache 2 0.8 0 0.0 2 0.8
 Insomnia 3 1.1 0 0.0 3 1.1
 Paralysis 1 0.4 0 0.0 1 0.4
Psychiatric disorders 9 3.4 1 0.4 10 3.8
 Aggression 3 1.1 0 0.0 3 1.1
 Depression 1 0.4 0 0.0 1 0.4
 Affective disorder 1 0.4 0 0.0 1 0.4
 Dysphemia 1 0.4 0 0.0 1 0.4
 Mood swings 1 0.4 0 0.0 1 0.4
 Emotional disorders of childhood 1 0.4 0 0.0 1 0.4
 Sleep disorder 1 0.4 1 0.4 1 0.4
Gastrointestinal disorders 8 3.1 0 0.0 8 3.1
 Nausea 4 1.5 0 0.0 4 1.5
 Abdominal pain 4 1.5 0 0.0 4 1.5
General disorders & administration site conditions 2 0.8 1 0.4 3 1.1
 Decreased activity 0 0.0 1 0.4 1 0.4
 Rebound effect 1 0.4 0 0.0 1 0.4
 Asthenia 1 0.4 0 0.0 1 0.4
Investigations 3 1.1 0 0.0 3 1.1
 Weight decreased 3 1.1 0 0.0 3 1.1
Skin and subcutaneous tissue disorders 1 0.4 0 0.0 1 0.4
 Rash 1 0.4 0 0.0 1 0.4
Respiratory, thoracic and mediastinal disorders 1 0.4 0 0.0 1 0.4
 Chest discomfort 1 0.4 0 0.0 1 0.4
Social circumstances 1 0.4 0 0.0 1 0.4
 Educational problem 1 0.4 0 0.0 1 0.4